PedAM
Pediatric Disease Annotations & Medicines
| Disease | neuropathy |
| Phenotype | C0026764|multiple myeloma |
| Sentences | 17 |
| PubMedID- 24867959 | A pilot study of acupuncture in treating bortezomib-induced peripheral neuropathy in patients with multiple myeloma. |
| PubMedID- 21749306 | Prevalence of peripheral neuropathy in multiple myeloma at initial diagnosis. |
| PubMedID- 21245421 | Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. |
| PubMedID- 20932799 | Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. |
| PubMedID- 22229320 | In a severe condition such as painful neuropathy associated with multiple myeloma and chemotherapy, a safe substance such as pea provides significant restoration of nerve function. |
| PubMedID- 22297012 | Bortezomib-induced peripheral neuropathy in patients with multiple myeloma. |
| PubMedID- 24596530 | Bortezomib-induced painful neuropathy in patients with multiple myeloma. |
| PubMedID- 23372151 | Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (rvd) therapy. |
| PubMedID- 25154818 | Subclinical peripheral neuropathy in patients with multiple myeloma before chemotherapy is correlated with decreased fingertip innervation density. |
| PubMedID- 24505516 | The condition may occur before initiating treatment.32 in a recent study by borrello et al., the incidence of peripheral neuropathy in patients with newly diagnosed multiple myeloma prior to the administration of any therapy was 15% which suggests that peripheral neuropathy is a symptom of the disease itself.33 furthermore, treating multiple myeloma might complicate the neuropathy; the latter is associated with agents used to treat the disease, such as bortezomib,7 thalidomide,34 and vincristine.35 recently, wilson and vallance-owen have suggested an interaction between myeloma-related factors and the patient's genetic background in the development of treatment-induced peripheral neuropathy with different molecular pathways being implicated in bortezomib-induced and vincristine-induced peripheral neuropathy.29 patients frequently complain of sensory symptoms, pain in a stocking-and-glove distribution, and proprioception changes that may affect normal daily living activities.36 studies looking into the association between bortezomib-induced neuropathy and diabetic neuropathy have yielded contradictory results. |
| PubMedID- 20467223 | [severe bortezomib-induced peripheral neuropathy in a patient with multiple myeloma]. |
| PubMedID- 22193964 | Management of treatment-emergent peripheral neuropathy in multiple myeloma. |
| PubMedID- 20671999 | neuropathy in patients with multiple myeloma can result in significant disability and impairment in quality of life. |
| PubMedID- 22363889 | In a recent study by borrello et al., the incidence of peripheral neuropathy in patients with newly diagnosed multiple myeloma prior to the administration of any therapy was 15% which suggests that peripheral neuropathy is a symptom of the disease itself [33]. |
| PubMedID- 25399783 | Therapy-related peripheral neuropathy in multiple myeloma patients. |
| PubMedID- 22110934 | Peripheral neuropathy in patients with multiple myeloma occurs as both disease- and treatment-related complication in the relapsed and newly diagnosed setting. |
| PubMedID- 21654882 | Its marked safety and comparable efficacy in multiple myeloma patients with pre-existing peripheral neuropathy makes it a drug that will integrate well with other active agents. |
Page: 1